# A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

> **NCT03219333** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 219 (actual)

## Conditions studied

- Carcinoma, Transitional Cell
- Urinary Bladder Neoplasms
- Urologic Neoplasms
- Renal Pelvis Neoplasms
- Urothelial Cancer
- Ureteral Neoplasms
- Urethral Neoplasms

## Interventions

- **DRUG:** Enfortumab vedotin

## Key facts

- **NCT ID:** NCT03219333
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-08
- **Primary completion:** 2020-10-27
- **Final completion:** 2023-07-28
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2024-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03219333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03219333, "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03219333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*